You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase Ib/II

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial in Shanghai (JS015, Toripalimab, Paclitaxel)

Not yet recruiting
  • Advanced Solid Tumor
  • JS015
  • +10 more
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Nov 17, 2023

Advanced Solid Tumors Trial (AK127 in combination with AK112)

Not yet recruiting
  • Advanced Solid Tumors
  • AK127 in combination with AK112
  • (no location specified)
Jul 11, 2023

Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)

Recruiting
  • Sarcoma
  • Fluzoparib+ Dalpiciclib
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023

Advanced Solid Tumors Trial (SHR-A2009 for injection ; Almonertinib Mesilate Tablets, SHR-A2009 for injection;Adebrelimab

Not yet recruiting
  • Advanced Solid Tumors
  • SHR-A2009 for injection ； Almonertinib Mesilate Tablets
  • SHR-A2009 for injection；Adebrelimab Injection
  • (no location specified)
Oct 17, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Advanced Solid Tumors Trial (PE0116,PE0105)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Sep 6, 2023

NASH, NAFLD Trial in Hangzhou (GH509, Placebo)

Recruiting
  • NASH
  • NAFLD
  • Hangzhou, Zhejiang, China
    The Affiliated Hospital of Hangzhou Normal University
Mar 26, 2023

Advanced Solid Tumor Trial (Adebrelimab, SHR-1802, Carboplatin/Cisplatin)

Not yet recruiting
  • Advanced Solid Tumor
  • Adebrelimab
  • +3 more
  • (no location specified)
Mar 20, 2023

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

Recruiting
  • Inhibition of Autophagy Synergizes Anti-tumor Effect
  • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
  • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023

Melanoma Trial in Beijing (IBI363)

Not yet recruiting
  • Melanoma
  • IBI363
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 7, 2023

Advanced Liver Cancer Trial in Chengdu (QL1706, QL1604, Bevacizumab)

Recruiting
  • Advanced Liver Cancer
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 1, 2022

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)

Not yet recruiting
  • Esophagogastric Adenocarcinoma
  • Sacituzumab govitecan
  • (no location specified)
Nov 9, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2023

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

Acute Lymphoblastic Leukemia Trial in Tianjin (CN201)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 14, 2022

Serous Ovarian Cancer, Advanced Ovarian Cancer Trial (SC0191, Gemcitabine, Paclitaxel)

Not yet recruiting
  • Serous Ovarian Cancer
  • Advanced Ovarian Cancer
  • (no location specified)
Sep 20, 2023

Hepatocellular Carcinoma Trial in Shanghai (BC3402 injection, Durvalumab injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • BC3402 injection
  • Durvalumab injection
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 26, 2023

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

TNBC Trial in Shanghai (PM8002, nab-paclitaxel)

Recruiting
  • TNBC
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2023

Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

Not yet recruiting
  • Locally Advanced Biliary Tract Cancer
  • Metastatic Biliary Tract Cancer
  • Camrelizumab and Apatinib Plus GP
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Feb 15, 2023

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2023

Advanced Renal Cell Carcinoma Trial in Beijing (ST-1898 tablets)

Recruiting
  • Advanced Renal Cell Carcinoma
  • ST-1898 tablets
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Nov 6, 2023